Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018
- January 2018
- 40 pages
DelveInsight's, Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report provides comprehensive insights about marketed and Phase III products for Relapsing Multiple Sclerosis (RMS) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.
Global API Manufacturers of Marketed Products for Relapsing Multiple Sclerosis (RMS)
Coverage of API manufacturers for Relapsing Multiple Sclerosis (RMS) marketed products spanning across United States, Europe, China and India. The manufacturers details include manufacturers name along with their location.
Emerging Phase III products for Relapsing Multiple Sclerosis (RMS)
This report provides a comprehensive understanding of the emerging Phase III therapies for Relapsing Multiple Sclerosis (RMS) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.
A review of the marketed products for Relapsing Multiple Sclerosis (RMS) including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details.
Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details
API manufacturers for the marketed products with location details
Emerging Phase III product profiles for Relapsing Multiple Sclerosis (RMS) including product description, developmental activities, licensors & collaborators and chemical information
Reasons to Buy
API intelligence for marketed drugs for the indication and gaining insights of API manufacturers
Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication
Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space
Have query on this report?Make an Enquiry
2. Relapsing Multiple Sclerosis (RMS) : Overview
Table 2: Drug Product Details, United States
Table 3: Drug Product Details, Europe
Table 4: Drug, Historical Global Sales till 2017 (in million USD)
Table 5: Drug, Forecasted Global Sales from 2018-2020 (in million USD)
Table 6: API Manufacturers Region wise
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017